ATE431396T1 - Für hcv-infektion geeignete zusammensetzungen und verfahren - Google Patents

Für hcv-infektion geeignete zusammensetzungen und verfahren

Info

Publication number
ATE431396T1
ATE431396T1 AT02753872T AT02753872T ATE431396T1 AT E431396 T1 ATE431396 T1 AT E431396T1 AT 02753872 T AT02753872 T AT 02753872T AT 02753872 T AT02753872 T AT 02753872T AT E431396 T1 ATE431396 T1 AT E431396T1
Authority
AT
Austria
Prior art keywords
compositions
hcv
methods
hcv infection
methods suitable
Prior art date
Application number
AT02753872T
Other languages
English (en)
Inventor
Ann Kwong
Randal Byrn
Lola Reid
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE431396T1 publication Critical patent/ATE431396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/18—Liver cell growth factor (LCGF, Gly-His-Lys)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/375—Thyroid stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
AT02753872T 2001-03-27 2002-03-27 Für hcv-infektion geeignete zusammensetzungen und verfahren ATE431396T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27917401P 2001-03-27 2001-03-27
PCT/US2002/009685 WO2002077206A1 (en) 2001-03-27 2002-03-27 Compositiona and methods useful for hcv infection

Publications (1)

Publication Number Publication Date
ATE431396T1 true ATE431396T1 (de) 2009-05-15

Family

ID=23067944

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02753872T ATE431396T1 (de) 2001-03-27 2002-03-27 Für hcv-infektion geeignete zusammensetzungen und verfahren

Country Status (15)

Country Link
US (3) US7879606B2 (de)
EP (1) EP1381673B1 (de)
JP (2) JP4499990B2 (de)
KR (1) KR100947911B1 (de)
CN (1) CN100362095C (de)
AT (1) ATE431396T1 (de)
CA (1) CA2441688C (de)
DE (1) DE60232322D1 (de)
ES (1) ES2328466T3 (de)
HK (1) HK1063334A1 (de)
MX (1) MXPA03008882A (de)
NO (1) NO20034278L (de)
NZ (1) NZ528462A (de)
WO (1) WO2002077206A1 (de)
ZA (1) ZA200307373B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
WO2004051218A2 (en) 2002-12-04 2004-06-17 Applera Corporation Multiplex amplification of polynucleotides
AR045596A1 (es) 2003-09-05 2005-11-02 Vertex Pharma Inhibidores de proteasas de serina en particular proteasa ns3-ns4a del vhc
US20050287514A1 (en) * 2003-12-01 2005-12-29 Vertex Pharmaceuticals Incorporated Compositions and methods useful for HCV infection
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CA2643688A1 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
EP1993994A2 (de) 2006-03-16 2008-11-26 Vertex Pharmceuticals Incorporated Deuterierte hepatitis-c-protease-hemmer
GEP20125645B (en) 2007-02-27 2012-09-25 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
MX2009009176A (es) 2007-02-27 2009-09-28 Vertex Pharma Inhibidores de serina-proteasas.
JP5443360B2 (ja) 2007-08-30 2014-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド 共結晶体およびそれを含む医薬組成物
CA2707841C (en) * 2007-12-04 2017-10-24 Prionics Ag Kit and method for detecting bovine viral diarrhea virus in tissue samples
CN101906487A (zh) * 2010-08-05 2010-12-08 中国兽医药品监察所 一种猪瘟病毒核酸标准物质的制备方法
AU2013308113B2 (en) * 2012-08-31 2019-01-17 The Governors Of The University Of Alberta Methods for producing cells having a phenotype of a primary human hepatocytes and compositions
WO2016174130A1 (en) * 2015-04-28 2016-11-03 Université De Strasbourg Clinical gene signature-based human cell culture model and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529920A (en) * 1988-12-14 1996-06-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human liver epithelial cell line and culture media therefor
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
EP1559778A1 (de) * 1991-08-07 2005-08-03 Albert Einstein College Of Medicine Of Yeshiva University Proliferation von Hepatozytenvorläufern
US6069005A (en) * 1991-08-07 2000-05-30 Albert Einstein College Of Medicine Of Yeshwa University Hapatoblasts and method of isolating same
CA2177043C (en) 1993-11-19 2011-08-09 Lola C.M. Reid Hepatoblasts and method of isolating same
CA2228128C (fr) * 1995-08-01 2011-03-29 Pasteur Merieux Serums & Vaccins Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
CA2272820C (en) * 1996-11-20 2012-09-11 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6133030A (en) * 1997-05-14 2000-10-17 The General Hospital Corporation Co-cultivation of cells in a micropatterned configuration
FR2775983B1 (fr) * 1998-03-13 2000-11-10 Pasteur Merieux Serums Vacc Milieu et procede de propagation et de multiplication virales
EP0972828A1 (de) * 1998-06-24 2000-01-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verfahren zur in vitro Replikation von HCV
ATE462014T1 (de) * 1998-12-07 2010-04-15 Univ Duke Bodipy aminoacetaldehyd diethyl acetal
JP5068901B2 (ja) 1999-01-19 2012-11-07 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ヒト肝前駆細胞
US20020187133A1 (en) * 1999-10-01 2002-12-12 Hiroshi Kubota Methods of isolating bipotent hepatic progenitor cells
PT1252293E (pt) 2000-01-19 2013-01-23 Univ North Carolina Fonte de tecido de fígado
JP2004510432A (ja) 2000-10-03 2004-04-08 ユニバーシティ　オブ　ノース　カロライナ 両能性肝前駆細胞の単離方法
CN1461341A (zh) 2000-10-03 2003-12-10 北卡罗来纳大学 肝祖先细胞克隆生长的方法
CN1592794A (zh) * 2001-03-09 2005-03-09 加利福尼亚大学董事会 用于合成感染性丙型肝炎病毒的细胞培养系统
EP1565552A4 (de) * 2002-07-01 2006-05-10 Pharmacia Corp Bei angiogenese differentiell exprimiertes esm-1-gen, antagonisten davon und verfahren zur verwendung davon

Also Published As

Publication number Publication date
HK1063334A1 (en) 2004-12-24
ZA200307373B (en) 2005-06-29
EP1381673A1 (de) 2004-01-21
JP2004529637A (ja) 2004-09-30
WO2002077206A1 (en) 2002-10-03
MXPA03008882A (es) 2003-12-08
US7879606B2 (en) 2011-02-01
JP4499990B2 (ja) 2010-07-14
CA2441688C (en) 2014-01-21
US20110229874A1 (en) 2011-09-22
CN100362095C (zh) 2008-01-16
KR20040012739A (ko) 2004-02-11
JP2010142249A (ja) 2010-07-01
EP1381673B1 (de) 2009-05-13
US20130071834A1 (en) 2013-03-21
NZ528462A (en) 2005-11-25
US20020142449A1 (en) 2002-10-03
NO20034278D0 (no) 2003-09-25
WO2002077206A9 (en) 2004-02-19
DE60232322D1 (de) 2009-06-25
KR100947911B1 (ko) 2010-03-17
US8211696B2 (en) 2012-07-03
CN1511190A (zh) 2004-07-07
NO20034278L (no) 2003-11-25
CA2441688A1 (en) 2002-10-03
ES2328466T3 (es) 2009-11-13
EP1381673A4 (de) 2004-11-10

Similar Documents

Publication Publication Date Title
ATE431396T1 (de) Für hcv-infektion geeignete zusammensetzungen und verfahren
DE60232234D1 (de) Verfahren zur kultivierung von circovirus
ATE419388T1 (de) Nukleinsäureanreicherung
DE60234464D1 (de) Zusammensetzungen und Verfahren zur selektiven Nukleinsäureisolierung
ECSP045255A (es) Cumarinas utiles como biomarcadores
ATE483825T1 (de) Zusammensetzungen für die identifizierung von adenoviren
BRPI0612409B8 (pt) composições de tensoativos à base de ácido peroxicarboxílico e método de reduzir a população de microorganismos em um objeto
MX2018012512A (es) Poblaciones de celula madre de la placenta.
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
ATE469219T1 (de) Zusammensetzungen, methoden und reagentien zur nukleinsäureisolierung mittels oberflächenaktiven substanzen und proteasen
ATE461990T1 (de) Zusammensetzung für die gewebepflege
ECSP066467A (es) Formas Polimórficas de 3-(4-amino-1-Oxo-1-3 DIhidroisoindol-2-IL)-Piperidin-2,6-Diona
DE602005019156D1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
TW200619287A (en) Composition and method
TW200732349A (en) Anti-OX40L antibodies and methods using same
DE602004030372D1 (de) Verfahren zur Bestimmung des relativen genetischen Risikos für Autismus
DE102005053064A1 (de) Verfahren zur Herstellung von Pfropfpolymerisaten
MA33210B1 (fr) Nouveaux anticorps anti-a5b1 et leurs utilisations
SG148182A1 (en) Antiloading compositions and methods of selecting same
ATE344321T1 (de) Verfahren zur aufreinigung von bakterienzellen und zellbestandteilen
MX2007013470A (es) Forma purificada de tanaproget.
MY162185A (en) Alumina particles and methods of making the same
ATE532875T1 (de) Reinigungsverfahren und ihre verwendungen
ATE524556T1 (de) Verfahren zur zyklischen nukleotid-bestimmung
ATE406461T1 (de) Rna-bioassay

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties